BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 30471630)

  • 1. Amyloid beta-positive subjects exhibit longitudinal network-specific reductions in spontaneous brain activity.
    Avants BB; Hutchison RM; Mikulskis A; Salinas-Valenzuela C; Hargreaves R; Beaver J; Chiao P;
    Neurobiol Aging; 2019 Feb; 74():191-201. PubMed ID: 30471630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
    Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
    Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrovascular resistance: effects on cognitive decline, cortical atrophy, and progression to dementia.
    Yew B; Nation DA;
    Brain; 2017 Jul; 140(7):1987-2001. PubMed ID: 28575149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inter-network connectivity and amyloid-beta linked to cognitive decline in preclinical Alzheimer's disease: a longitudinal cohort study.
    Van Hooren RWE; Riphagen JM; Jacobs HIL;
    Alzheimers Res Ther; 2018 Aug; 10(1):88. PubMed ID: 30153858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum.
    Tosun D; Schuff N; Jagust W; Weiner MW;
    Neurodegener Dis; 2016; 16(1-2):87-94. PubMed ID: 26560336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease.
    Jack CR; Wiste HJ; Vemuri P; Weigand SD; Senjem ML; Zeng G; Bernstein MA; Gunter JL; Pankratz VS; Aisen PS; Weiner MW; Petersen RC; Shaw LM; Trojanowski JQ; Knopman DS;
    Brain; 2010 Nov; 133(11):3336-48. PubMed ID: 20935035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology.
    Schreiber S; Schreiber F; Lockhart SN; Horng A; Bejanin A; Landau SM; Jagust WJ;
    JAMA Neurol; 2017 Jun; 74(6):650-659. PubMed ID: 28319241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Education on Alzheimer's Disease-Related Neuroimaging Biomarkers in Healthy Controls, and Participants with Mild Cognitive Impairment and Alzheimer's Disease: A Cross-Sectional Study.
    Wada M; Noda Y; Shinagawa S; Chung JK; Sawada K; Ogyu K; Tarumi R; Tsugawa S; Miyazaki T; Yamagata B; Graff-Guerrero A; Mimura M; Nakajima S;
    J Alzheimers Dis; 2018; 63(2):861-869. PubMed ID: 29689728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between educational attainment and amyloid deposition across the spectrum from normal cognition to dementia: neuroimaging evidence for protection and compensation.
    Arenaza-Urquijo EM; Bejanin A; Gonneaud J; Wirth M; La Joie R; Mutlu J; Gaubert M; Landeau B; de la Sayette V; Eustache F; Chételat G
    Neurobiol Aging; 2017 Nov; 59():72-79. PubMed ID: 28764930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
    Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
    Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Visual and Quantitative Florbetapir F 18 Positron Emission Tomography Analysis in Predicting Mild Cognitive Impairment Outcomes.
    Schreiber S; Landau SM; Fero A; Schreiber F; Jagust WJ;
    JAMA Neurol; 2015 Oct; 72(10):1183-90. PubMed ID: 26280102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Left lateralized cerebral glucose metabolism declines in amyloid-β positive persons with mild cognitive impairment.
    Weise CM; Chen K; Chen Y; Kuang X; Savage CR; Reiman EM;
    Neuroimage Clin; 2018; 20():286-296. PubMed ID: 30101060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spatial Patterns of Longitudinal Gray Matter Change as Predictors of Concurrent Cognitive Decline in Amyloid Positive Healthy Subjects.
    Araque Caballero MÁ; Klöppel S; Dichgans M; Ewers M;
    J Alzheimers Dis; 2017; 55(1):343-358. PubMed ID: 27662291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
    Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
    Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
    Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
    Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disrupted Intrinsic Networks Link Amyloid-β Pathology and Impaired Cognition in Prodromal Alzheimer's Disease.
    Koch K; Myers NE; Göttler J; Pasquini L; Grimmer T; Förster S; Manoliu A; Neitzel J; Kurz A; Förstl H; Riedl V; Wohlschläger AM; Drzezga A; Sorg C
    Cereb Cortex; 2015 Dec; 25(12):4678-88. PubMed ID: 24996404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Electromagnetic signatures of the preclinical and prodromal stages of Alzheimer's disease.
    Nakamura A; Cuesta P; Fernández A; Arahata Y; Iwata K; Kuratsubo I; Bundo M; Hattori H; Sakurai T; Fukuda K; Washimi Y; Endo H; Takeda A; Diers K; Bajo R; Maestú F; Ito K; Kato T
    Brain; 2018 May; 141(5):1470-1485. PubMed ID: 29522156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease.
    Lim YY; Maruff P; Pietrzak RH; Ames D; Ellis KA; Harrington K; Lautenschlager NT; Szoeke C; Martins RN; Masters CL; Villemagne VL; Rowe CC;
    Brain; 2014 Jan; 137(Pt 1):221-31. PubMed ID: 24176981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive consequences of high Aβ amyloid in mild cognitive impairment and healthy older adults: implications for early detection of Alzheimer's disease.
    Lim YY; Ellis KA; Harrington K; Kamer A; Pietrzak RH; Bush AI; Darby D; Martins RN; Masters CL; Rowe CC; Savage G; Szoeke C; Villemagne VL; Ames D; Maruff P;
    Neuropsychology; 2013 May; 27(3):322-332. PubMed ID: 23688214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.